BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™.

GC Pharma announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration in response to its Biologics License Application for ‘GC5107’.

Legend Biotech Corporation announced that the U.S. Food and Drug Administration has approved its first product, CARVYKTI™, for the treatment of adults with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided additional corporate updates.

West Pharmaceutical Services, Inc. announced Eric M. Green, President and CEO, will assume the additional responsibility of Chair of the Company’s Board of Directors, effective as of West’s next Annual Shareholders’ Meeting, which is expected to be May 24, 2022.

Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, today reported its financial results for the full year 2021, its recent business highlights, and a preview of anticipated select milestones in 2022.

Taro Pharmaceutical Industries Ltd. announced the completion of its acquisition of Alchemee, formerly The Proactiv Company, from Galderma.

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.